AR027956A1 - Nuevas combinaciones de farmacos - Google Patents

Nuevas combinaciones de farmacos

Info

Publication number
AR027956A1
AR027956A1 ARP010100838A ARP010100838A AR027956A1 AR 027956 A1 AR027956 A1 AR 027956A1 AR P010100838 A ARP010100838 A AR P010100838A AR P010100838 A ARP010100838 A AR P010100838A AR 027956 A1 AR027956 A1 AR 027956A1
Authority
AR
Argentina
Prior art keywords
pharmacos
combinations
new
pharmacos combinations
new pharmacos
Prior art date
Application number
ARP010100838A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of AR027956A1 publication Critical patent/AR027956A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP010100838A 2000-02-24 2001-02-23 Nuevas combinaciones de farmacos AR027956A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18479000P 2000-02-24 2000-02-24

Publications (1)

Publication Number Publication Date
AR027956A1 true AR027956A1 (es) 2003-04-16

Family

ID=22678338

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100838A AR027956A1 (es) 2000-02-24 2001-02-23 Nuevas combinaciones de farmacos

Country Status (16)

Country Link
US (1) US20020010216A1 (es)
EP (1) EP1257277B1 (es)
JP (1) JP2003523382A (es)
CN (2) CN1660435A (es)
AR (1) AR027956A1 (es)
AT (1) ATE297735T1 (es)
AU (1) AU781254B2 (es)
CA (1) CA2399442A1 (es)
DE (1) DE60111500T2 (es)
DK (1) DK1257277T3 (es)
ES (1) ES2241802T3 (es)
MX (1) MXPA02008183A (es)
NZ (1) NZ520975A (es)
PE (1) PE20011306A1 (es)
PT (1) PT1257277E (es)
WO (1) WO2001062236A2 (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500395B1 (en) * 1999-07-01 2006-03-08 Pharmacia & Upjohn Company LLC Reboxetine for treating fibromyalgia and other somatoform disorders
PT1632234E (pt) 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
MXPA04000979A (es) * 2001-07-31 2005-02-17 Upjohn Co Tratamiento de dolor cronico con 3-ariloxi-3-fenilpropanaminas.
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10146275A1 (de) 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20050014843A1 (en) * 2001-11-30 2005-01-20 Allen Albert John Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
US7754242B2 (en) * 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
EP1485344A1 (en) * 2002-03-28 2004-12-15 Synthon B.V. Venlafaxine besylate
US6696496B2 (en) * 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
WO2004019892A2 (en) * 2002-08-30 2004-03-11 Watson Pharmaceuticals, Inc. Drug delivery system for treating urinary incontinence
CA2500662A1 (en) * 2002-10-03 2004-04-15 Cypress Bioscience, Inc. Dosage escalation and divided daily dose of anti-depressants to treat neurological disorders
US6974820B2 (en) * 2002-11-06 2005-12-13 Bridge Pharma, Inc. Methods for treating urinary incontinence and other disorders using trospium
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
WO2004058353A2 (en) * 2002-12-24 2004-07-15 Paradigm Therapeutics Ltd. Therapeutic use of selective noradrenaline reuptake inhibitors
US6943193B1 (en) * 2003-01-21 2005-09-13 Jordan A. Altabet Method for treating sexual dysfunction
PT1601349E (pt) * 2003-02-14 2008-10-27 Pf Medicament Utilização do enantiómero (1s, 2r) do milnaciprano para a preparação de um medicamento
FR2851163B1 (fr) 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
DE602004007225T2 (de) * 2003-04-04 2008-03-06 Dynogen Pharmaceuticals Inc., Waltham Methode zur behandlung von erkrankungen der unteren harnwege
JP2006524708A (ja) * 2003-04-25 2006-11-02 インディヴァス ファーマシューティカルズ，インコーポレーテッド 塩化トロスピウムの投与により連続睡眠を促進するための方法
CA2536161A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
EP1680110B1 (en) 2003-11-04 2011-01-05 Supernus Pharmaceuticals, Inc. Once daily dosage forms of trospium
EP1680100A4 (en) 2003-11-04 2012-08-08 Supernus Pharmaceuticals Inc QUATERNARY AMMONIUM COMPOUNDS CONTAINING BIOAVAILABILITY ACTIVATORS
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
CA2576386A1 (en) * 2004-08-13 2006-02-16 Boehringer Ingelheim International Gmbh Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
PL1789021T3 (pl) * 2004-08-13 2012-04-30 Boehringer Ingelheim Int Preparat tabletkowy o przedłużonym uwalnianiu zawierający pramipeksol lub jego farmaceutycznie dopuszczalną sól
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び／又は予防用の医薬組成物
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7390816B2 (en) * 2005-06-21 2008-06-24 Bridge Pharma, Inc. Methods for treating urinary incontinence in patients suffering from memory disorders
US20060287347A1 (en) * 2005-06-21 2006-12-21 Aberg A K G Methods for treating smooth muscle disorders using trospium
US20070004766A1 (en) * 2005-07-01 2007-01-04 Aberg A K G Methods for relaxation of smooth muscle contractions using Trospium
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007128802A2 (en) * 2006-05-09 2007-11-15 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AR062321A1 (es) * 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
IT1392333B1 (it) * 2008-12-16 2012-02-28 Giofarma S R L Preparazione farmaceutica per il trattamento di patologie depressive, contenente una proteina con elevato rapporto triptofano/lnaa
CA2804215C (en) * 2009-07-22 2019-10-01 Eric Elenko Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
CA2779711C (en) 2009-11-06 2016-11-01 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
WO2011130194A2 (en) 2010-04-12 2011-10-20 Supernus Pharmaceuticals Inc. Methods for producing viloxazine salts and novel polymorphs thereof
US20120289744A1 (en) 2010-11-03 2012-11-15 Arch Pharmalabs Limited Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts
US11123313B2 (en) * 2017-04-28 2021-09-21 The Brigham And Women's Hospital, Inc. Methods and compositions for treating sleep apnea
AU2019214891B2 (en) * 2018-01-30 2024-08-01 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
JP2022506113A (ja) * 2018-10-31 2022-01-17 アプニメッド，インコーポレイテッド（デラウェア） 睡眠時無呼吸を治療するための方法及び組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
GB9517883D0 (en) * 1995-09-01 1995-11-01 Euro Celtique Sa Improved pharmaceutical ion exchange resin composition

Also Published As

Publication number Publication date
JP2003523382A (ja) 2003-08-05
EP1257277B1 (en) 2005-06-15
EP1257277A2 (en) 2002-11-20
MXPA02008183A (es) 2002-11-29
CN1396829A (zh) 2003-02-12
PE20011306A1 (es) 2001-12-29
CN1660435A (zh) 2005-08-31
WO2001062236A2 (en) 2001-08-30
US20020010216A1 (en) 2002-01-24
NZ520975A (en) 2004-03-26
PT1257277E (pt) 2005-09-30
ES2241802T3 (es) 2005-11-01
AU3802801A (en) 2001-09-03
DK1257277T3 (da) 2005-09-12
DE60111500T2 (de) 2006-05-18
WO2001062236A3 (en) 2002-03-07
DE60111500D1 (de) 2005-07-21
CA2399442A1 (en) 2001-08-30
AU781254B2 (en) 2005-05-12
ATE297735T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
AR027956A1 (es) Nuevas combinaciones de farmacos
PT1259508E (pt) Novos biarilcarboxamidas
ATE290000T1 (de) Muscarinagonisten
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DE50100710D1 (de) Wischblatt
ATE262530T1 (de) Indolochinazolinone
ATE298751T1 (de) 7-oxopyridoryrimidine
PT1268453E (pt) Metabolitos de agonista/antagonista de estrogenio
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50011511D1 (de) Blowby-Heizung
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
PT1317179E (pt) Formulacoes de mesotriona
AR027931A1 (es) Antitranspirantes
DE50007634D1 (de) Kardioplegieballonkatheter
ATE476423T1 (de) Benzoylpyridazine
DE10052925B4 (de) Schaukelbett
DE10085445T1 (de) Drahterodierbearbeitungseinrichtung
DE10195909T1 (de) Viehfüttervorrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos
DE10195992T1 (de) Oberflächenendbearbeitungsbelag

Legal Events

Date Code Title Description
FB Suspension of granting procedure